Bronte Capital Management’s Pacific Biosciences PACB Stock Holding History

Bronte Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30K	Buy	+17,881	New	+$26K	﹤0.01%	50

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bronte Capital Management's PACB Position: Q2 2026 in Review

Bronte Capital Management opened a new position in Pacific Biosciences (PACB) in Q2 2026: 17,881 shares worth $30K. The stake represents ﹤0.01% of the portfolio and ranks #50 among its holdings.

223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Bronte Capital Management held 17,881 shares of Pacific Biosciences worth $30K as of Q2 2026.
Pacific Biosciences was a new Bronte Capital Management position in Q2 2026.
Pacific Biosciences made up ﹤0.01% of Bronte Capital Management's portfolio in Q2 2026, its #50 holding.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.